We are working closely with Japan to promote research into novel antimicrobial products and to address the global market failures in antibiotic research and development. Professor Dame Sally Davies, the United Kingdom Special Envoy on Antimicrobial Resistance (AMR), visited Japan earlier this year and met with parliamentarians, senior officials and industry leaders to highlight the threat posed by AMR and to share experiences from the world-leading NHS England and National Institute for Health and Care Excellence antimicrobial reimbursement project.<\/p>
Officials at the Department of Health and Social Care and the Foreign, Commonwealth and Development Office continue to have bilateral consultations with their Japanese counterparts on national research into new antimicrobial agents and UK Ministers also highlighted the importance of this during G7 Ministerial meetings. Collaboration on AMR also continues between UK Research and Innovation and the Japan Agency for Medical Research and Development under the Memorandum of Cooperation.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4948", "label" : {"_value" : "Biography information for Lord Markham"} } , "answeringMemberPrinted" : {"_value" : "Lord Markham"} , "dateOfAnswer" : {"_value" : "2023-07-17", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2023-07-17T16:57:31.17Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2023-07-11", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Antimicrobials: Research"} , "houseId" : {"_value" : "2"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"} } ], "questionText" : "To ask His Majesty's Government what discussions they have had with the government of Japan about bilateral collaboration into research into new antimicrobial agents and antimicrobial drugs.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4719", "label" : {"_value" : "Biography information for Baroness Bennett of Manor Castle"} } , "tablingMemberPrinted" : [{"_value" : "Baroness Bennett of Manor Castle"} ], "uin" : "HL9232"} , {"_about" : "http://data.parliament.uk/resources/1652130", "AnsweringBody" : [{"_value" : "Department for Work and Pensions"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1652130/answer", "answerText" : {"_value" : "
The Health and Safety at Work etc. Act 1974 establishes duties for manufacturers to design and construct safe articles for use at work. In the various health and safety regulations that apply to the oil and gas industry it is the responsibility of the duty holder to ensure that any components used are fit for purpose for their intended use, and that they have the means to ensure those components will remain fit for purpose during their service life. Furthermore, product supply legislation places duties on the manufacturers of such products to assess their safety before their use.<\/p>
<\/p>
The Health and Safety Executive (HSE) undertakes market surveillance monitoring of the health and safety of most products used at work. HSE have been engaged with the additive manufacturing industry for a number of years, including the publication of a report into structure properties of the technique in 2015. Industry standards and guidance are being produced in this area and these assure quality control throughout additive manufacture and provide a sufficient quantity and quality of information to manufacturers and dutyholders seeking to make or use these articles which can also be used as benchmarks against which to judge regulatory compliance. HSE is also considering the implications of exposure to fumes and respirable dusts from those undertaking additive manufacturing.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4169", "label" : {"_value" : "Biography information for Viscount Younger of Leckie"} } , "answeringMemberPrinted" : {"_value" : "Viscount Younger of Leckie"} , "dateOfAnswer" : {"_value" : "2023-07-19", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2023-07-19T11:43:45.183Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "29"} , "answeringDeptShortName" : {"_value" : "Work and Pensions"} , "answeringDeptSortName" : {"_value" : "Work and Pensions"} , "date" : {"_value" : "2023-07-11", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Offshore Industry: Safety"} , "houseId" : {"_value" : "2"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"} } ], "questionText" : "To ask His Majesty's Government what assessment they have made of the safety of additive manufacturer products in equipment in the oil and gas industries.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4719", "label" : {"_value" : "Biography information for Baroness Bennett of Manor Castle"} } , "tablingMemberPrinted" : [{"_value" : "Baroness Bennett of Manor Castle"} ], "uin" : "HL9234"} , {"_about" : "http://data.parliament.uk/resources/1651482", "AnsweringBody" : [{"_value" : "Department for Environment, Food and Rural Affairs"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1651482/answer", "answerText" : {"_value" : "
While we do not provide direct financial support for the development of veterinary clinical skill laboratories in low- and middle-income countries, we proactively support country and regional partners with Official Development Assistance funding to strengthen health systems, including through our £5m Animal Health Systems Strengthening Project, which is providing technical assistance and other capability-building to veterinary services in Africa.<\/p>
<\/p>
In addition, and to ensure the UK effectively drives better and sustainable health outcomes in low- and middle-income countries, our world-class laboratories are actively involved in delivering global health outreach programmes, including laboratory twinning projects to build diagnostic capability for the surveillance and detection of animal diseases.<\/p>
<\/p>
We have also developed and delivered e-learning modules for over 200 veterinary professionals and paraprofessionals working in low- and middle-income countries to build skills in laboratory diagnostics, surveillance strategies, pandemic preparedness training, epidemiology, and veterinary medicine residue surveillance.<\/p>
<\/p>
All UK Aid spend is published by the Foreign, Commonwealth and Development Office as Statistics on International Development, and is available at GOV.UK.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/1547", "label" : {"_value" : "Biography information for Lord Benyon"} } , "answeringMemberPrinted" : {"_value" : "Lord Benyon"} , "dateOfAnswer" : {"_value" : "2023-07-13", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2023-07-13T16:31:58.09Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "13"} , "answeringDeptShortName" : {"_value" : "Environment, Food and Rural Affairs"} , "answeringDeptSortName" : {"_value" : "Environment, Food and Rural Affairs"} , "date" : {"_value" : "2023-07-10", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Developing Countries: Veterinary Medicine"} , "houseId" : {"_value" : "2"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"} } ], "questionText" : "To ask His Majesty's Government whether, and if so to what extent, they provide direct financial support for the development of veterinary clinical skill laboratories in low- and middle-income countries to strengthen animal health systems.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4719", "label" : {"_value" : "Biography information for Baroness Bennett of Manor Castle"} } , "tablingMemberPrinted" : [{"_value" : "Baroness Bennett of Manor Castle"} ], "uin" : "HL9195"} , {"_about" : "http://data.parliament.uk/resources/1651483", "AnsweringBody" : [{"_value" : "Department for Environment, Food and Rural Affairs"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1651483/answer", "answerText" : {"_value" : "
The UK Government is committed to reducing unnecessary use of antibiotics in animals, while safeguarding animal welfare. It has been our position for many years that we do not support the routine or predictable use of antibiotics, including where antibiotics are used to compensate for inadequate farming practices. This applies to all types of antibiotic use (i.e those prescribed for treatment, metaphylactic purposes and for prophylactic purposes) because any antibiotic use may lead to an increased risk of resistance.<\/p>
<\/p>
The Veterinary Medicines Regulations 2013 are currently under review and the UK Government\u2019s proposed new legal restrictions will prohibit antibiotic prophylaxis, in all but exceptional circumstances, in order to reduce unnecessary antibiotic use while also protecting animal welfare, and allowing changes to prescribing practices to be made sustainably. A public consultation on the proposed changes was held earlier this year, feedback is currently being analysed and considered, and a government response will be published in due course.<\/p>
<\/p>
Highest Priority Critically Important Antibiotics for human use (which include fluoroquinolones) should only be used in animals as a last resort when no other antibiotics could be clinically effective and, wherever possible, based on antimicrobial susceptibility testing.<\/p>
<\/p>
The Veterinary Medicines Directorate works closely with the British Poultry Council (BPC), an industry group which represents 90% of the meat poultry sector in the UK, on its antimicrobial stewardship efforts to replace, reduce and refine antibiotic use, by supporting good animal husbandry, hygiene and stockmanship. The BPC has a requirement that fluoroquinolones are only used as a last resort after alternative options have been explored. These actions have led to a 96% reduction in fluroquinolone use in meat poultry between 2014 and 2021, with fluoroquinolones representing just 0.3% of total antibiotic use in 2021.<\/p>
<\/p>
Furthermore, when considering laying hens, antibiotic use data collected by the British Egg Industry Council, and representing 90% of the industry, has demonstrated no fluoroquinolone use since 2017.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/1547", "label" : {"_value" : "Biography information for Lord Benyon"} } , "answeringMemberPrinted" : {"_value" : "Lord Benyon"} , "dateOfAnswer" : {"_value" : "2023-07-14", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2023-07-14T12:13:32.967Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "13"} , "answeringDeptShortName" : {"_value" : "Environment, Food and Rural Affairs"} , "answeringDeptSortName" : {"_value" : "Environment, Food and Rural Affairs"} , "date" : {"_value" : "2023-07-10", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Poultry: Antibiotics"} , "houseId" : {"_value" : "2"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"} } ], "questionText" : "To ask His Majesty's Government what plans they have to ban the use of fluoroquinolone antibiotics for prophylactic and metaphylactic use in British poultry farming, with a view to limiting antimicrobial resistance.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4719", "label" : {"_value" : "Biography information for Baroness Bennett of Manor Castle"} } , "tablingMemberPrinted" : [{"_value" : "Baroness Bennett of Manor Castle"} ], "uin" : "HL9196"} , {"_about" : "http://data.parliament.uk/resources/1651487", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1651487/answer", "answerText" : {"_value" : "
The Pharmacy Access Scheme provides additional funding to pharmacies where the next nearest pharmacy is more than a 20-minute walk away. This is calculated as a 0.8-mile walking distance in areas of high deprivation and 1 mile in other areas. In 2021, we agreed updated eligibility criteria and an updated payment model with Community Pharmacy England. To be eligible for the payment, pharmacies must deliver the Community Pharmacist Consultation Service. Quality and opening hours are not included in the eligibility criteria.<\/ins><\/p> <\/p> <\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4948", "label" : {"_value" : "Biography information for Lord Markham"}
}
, "answeringMemberPrinted" : {"_value" : "Lord Markham"}
, "dateOfAnswer" : {"_value" : "2023-07-19", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "true", "_datatype" : "boolean"}
, "previousAnswerVersion" : {"_about" : "http://data.parliament.uk/resources/1651487/answer/previousversion/88780", "answeringMember" : {"_about" : "http://data.parliament.uk/members/4948", "label" : {"_value" : "Biography information for Lord Markham"}
}
, "answeringMemberPrinted" : {"_value" : "Lord Markham"}
}
, "questionFirstAnswered" : [{"_value" : "2023-07-19T15:05:50.113Z", "_datatype" : "dateTime"}
], "questionFirstMinisteriallyCorrected" : [{"_value" : "2023-07-20T15:18:01.373Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2023-07-10", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Pharmacy: Standards"}
, "houseId" : {"_value" : "2"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"}
}
], "questionText" : "To ask His Majesty's Government what assessment they have made of the level of support available under the Pharmacy Access Scheme; and whether the criteria includes the (1) quality, (2) opening hours, and (3) range of provision, of existing pharmacies.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4719", "label" : {"_value" : "Biography information for Baroness Bennett of Manor Castle"}
}
, "tablingMemberPrinted" : [{"_value" : "Baroness Bennett of Manor Castle"}
], "uin" : "HL9200"}
, {"_about" : "http://data.parliament.uk/resources/1651024", "AnsweringBody" : [{"_value" : "Department for Environment, Food and Rural Affairs"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1651024/answer", "answerText" : {"_value" : " Defra expects to publish the below PIRs as follows:<\/p> <\/p> (1) The African Horse Sickness (England) Regulations 2012 - July 2023<\/p> (2) The Animals and Animal Products (Examination for Residues and Maximum Residue Limits) (England and Scotland) Regulations 2015 - Autumn 2023<\/p> (3) The Veterinary Medicines Regulations 2013 - August 2023<\/p> (4) The Sea Fishing (Points for Masters of Fishing Boats) Regulations 2014 - September 2023<\/p> (5) The Alien and Locally Absent Species in Aquaculture (England and Wales) Regulations 2011 - July 2023<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/1547", "label" : {"_value" : "Biography information for Lord Benyon"}
}
, "answeringMemberPrinted" : {"_value" : "Lord Benyon"}
, "dateOfAnswer" : {"_value" : "2023-07-13", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2023-07-13T14:20:23.287Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "13"}
, "answeringDeptShortName" : {"_value" : "Environment, Food and Rural Affairs"}
, "answeringDeptSortName" : {"_value" : "Environment, Food and Rural Affairs"}
, "date" : {"_value" : "2023-07-06", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Department for Environment, Food and Rural Affairs: Statutory Instruments"}
, "houseId" : {"_value" : "2"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"}
}
], "questionText" : "To ask His Majesty's Government when they will publish the statutory post implementation reviews of (1) the African Horse Sickness (England) Regulations 2012, (2) the Animals and Animal Products (Examination for Residues and Maximum Residue Limits) (England and Scotland) Regulations 2015, (3) the Veterinary Medicines Regulations 2013, (4) the Sea Fishing (Points for Masters of Fishing Boats) Regulations 2014, and (5) the Alien and Locally Absent Species in Aquaculture (England and Wales) Regulations 2011.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4719", "label" : {"_value" : "Biography information for Baroness Bennett of Manor Castle"}
}
, "tablingMemberPrinted" : [{"_value" : "Baroness Bennett of Manor Castle"}
], "uin" : "HL9096"}
, {"_about" : "http://data.parliament.uk/resources/1651025", "AnsweringBody" : [{"_value" : "Home Office"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1651025/answer", "answerText" : {"_value" : " The Home Office collects and publishes information on the number of police recorded offences, and their investigative outcomes (including charges outcomes), on \u2018assaults on a constable\u2019 and the number of \u2018assaults on an emergency worker (other than a constable)\u2019 on a quarterly basis and that can be accessed here:<\/p>The early access to medicines scheme (EAMS) aims to give patients with life threatening or seriously debilitating conditions access to medicines that do not yet have a marketing authorisation when there is a clear unmet medical need.<\/del><\/p>Under the scheme, the Medicines and Healthcare products Regulatory Agency (MHRA) will give a scientific opinion on the benefit/risk balance of the medicine, based on the data available when the EAMS submission was made and the EAMS criteria. The MHRA will make an evaluation of products, including drugs such as for brain tumour treatments, once an application is received.<\/del><\/p>If we do receive an application, it is only made public where an EAMS Scientific Opinion (SO) is awarded. All EAMS SOs are published on the EAMS webpage. All drugs that have previously held an EAMS SO are also published on the EAMS webpage.<\/del><\/p>